AtkinsonMA, EisenbarthGS, MichelsAW: Type 1 diabetes. Lancet, 2014; 383:69–82.
2.
Diabetes Epidemiology Research International Group: Secular trends in incidence of childhood IDDM in 10 countries. Diabetes, 1990; 39:858–864.
3.
HarjutsaloV, SjobergL, TuomilehtoJ: Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study. Lancet, 2008; 371:1777–1782.
4.
VehikK, HammanRF, LezotteD, et al.: Increasing incidence of type 1 diabetes in 0- to 17-year-old Colorado youth. Diabetes Care, 2007; 30:503–509.
5.
ZieglerAG, RewersM, SimellO, et al.: Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA, 2013; 309:2473–2479.
6.
ParikkaV, Näntö-SalonenK, SaarinenM, et al.: Early seroconversion and rapidly increasing autoantibody concentrations predict prepubertal manifestation of type 1 diabetes in children at genetic risk. Diabetologia, 2012; 55:1926–1936.
7.
ZieglerAG, BonifacioE: BABYDIAB-BABYDIET Study Group. Age-related islet autoantibody incidence in offspring of patients with type 1 diabetes. Diabetologia, 2012; 55:1937–1943.
8.
O'LearyLA, DormanJS, LaPorteRE, et al.: Familial and sporadic insulin-dependent diabetes: evidence for heterogeneous etiologies?. Diab Res Clin Pract, 1991; 4:183–190.
9.
HämäläinenAM, KnipM: Autoimmunity and familial risk of type 1 diabetes. Curr Diab Rep, 2002; 2:347–353.
TornC, MuellerPW, SchlosserM, et al.: Diabetes antibody standardization program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2. Diabetologia, 2008; 51:846–852.
12.
SchlosserM, MuellerPW, TornC, et al.: Diabetes antibody standardization program: evaluation of assays for insulin autoantibodies. Diabetologia, 2010; 53:2611–2620.
13.
BonifacioE, YuL, WilliamsAK, et al.: Harmonization of glutamic acid decarboxylase and islet antigen-2 autoantibody assays for national institute of diabetes and digestive and kidney diseases consortia. J Clin Endocrinol Metab, 2010; 95:3360–3367.
14.
YuL, MiaoD, ScrimgeourL, et al.: Distinguishing persistent insulin autoantibodies with differential risk: nonradioactive bivalent proinsulin/insulin autoantibody assay. Diabetes, 2012; 61:179–186.
15.
YuL, DongF, MiaoD, et al.: Proinsulin/Insulin autoantibodies measured with electrochemiluminescent assay are the earliest indicator of prediabetic islet autoimmunity. Diabetes Care, 2013; 36:2266–2270.
16.
MiaoD, GuyerKM, DongF, et al.: GAD65 autoantibodies detected by electrochemiluminescence assay identify high risk for type 1 diabetes. Diabetes, 2013; 62:4174–4178.
17.
MiaoD, SteckAK, ZhangL, et al.: Electrochemiluminescence assays for insulin and glutamic acid decarboxylase autoantibodies improve prediction of type 1 diabetes risk. Diabetes Technol Ther, 2015; 17:119–127.
18.
SteckAK, FoutsA, MiaoD, et al.: ECL-IAA and ECL-GADA Can identify high-risk single autoantibody-positive relatives in the TrialNet pathway to prevention study. Diabetes Technol Ther, 2016; 18:410–414.
19.
ZhangB, KumarRB, DaiH, FeldmanBJ: A plasmonic chip for biomarker discovery and diagnosis of type 1 diabetes. Nat Med, 2014; 20:948–953.
YimSW, KimT, LaurenceTA, et al.: Four-color alternating-laser excitation single-molecule fluorescence spectroscopy for next-generation biodetection assays. Clin Chem, 2012; 58:707–716.
22.
BaleSS, PriceG, CasaliM, et al.: A highly sensitive microsphere-based assay for early detection of Type I diabetes. Technology, 2014; 02:200–205.
23.
ZieglerAG, HauptF, ScholzM, et al.: 3 Screen ELISA for high-throughput detection of beta cell autoantibodies in capillary blood. Diabetes Technol Ther, 2016; 18:687–693.
24.
RaabJ, HauptF, ScholzM, et al.: Capillary blood islet autoantibody screening for identifying pre-type 1 diabetes in the general population: design and initial results of the Fr1da study. BMJ Open, 2016; 6:e011144.
25.
BazzigaluppiE, BonfantiR, BingleyPJ, et al.: Capillary whole blood measurement of islet autoantibodies. Diabetes Care, 1999; 22:275–279.
26.
BingleyPJ, RafkinLE, MathesonD, et al.: Use of dried capillary blood sampling for islet autoantibody screening in relatives: a feasibility study. Diabetes Technol Ther, 2015; 17:867–871.
27.
GesualdoPD, BautistaKA, WaughKC, et al.: 2015. Feasibility of screening for T1D and celiac disease in a pediatric clinic setting. Pediatr Diabetes, 2016; 17:441–448.
28.
HummelM, BonifacioE, SchmidS, et al.: Brief communication: early appearance of islet autoantibodies predicts childhood type 1 diabetes in offspring of diabetic parents. Ann Intern Med, 2004; 140:882–886.
29.
WangJ, MiaoD, BabuS, et al.: Prevalence of autoantibody-negative diabetes is not rare at all ages and increases with older age and obesity. J Clin Endocrinol Metab, 2007; 92:88–92.
30.
SteckAK, JohnsonK, BarrigaKJ, et al.: Age of islet autoantibody appearance and mean levels of insulin, but not GAD or IA-2 autoantibodies, predict age of diagnosis of type 1 diabetes: diabetes autoimmunity study in the young. Diabetes Care, 2011; 34:1397–1399.
31.
ZhaoZ, MiaoD, MichelsA, et al.: A multiplex assay combining insulin, GAD, IA-2 and transglutaminase autoantibodies to facilitate screening for pre-type 1 diabetes and celiac disease. J Immunol Methods, 2016; 430:28–32.
32.
ZhaoZ, MiaoD, MichelsA, et al.: A multiplex assay for simultaneous screening type 1 diabetes and multiple autoimmune diseases. Diabetes, 2016; 65Suppl.1:1419.
33.
MathewA, WangM, BarberoS, et al.: Multiplexed assay panels for prediction/diagnosis of type 1 diabetes (T1D) and comorbid autoimmune diseases. Diabetes, 2016; 65Suppl.1:1673.
